FEDERAL COURT OF AUSTRALIA
Ranbaxy Australia Pty Ltd (ACN 110 781 826) v Warner-Lambert Company LLC [2008] FCAFC 82
PATENTS – construction of patent – construction of specification – common general knowledge in relevant field of art – whether patent is restricted to the racemate of a claimed compound or extends to the enantiomers of the compounds individually and mixtures of the enantiomers
PATENTS – revocation of patent – whether patent obtained by false suggestion or misrepresentation – representation in specification – representation in correspondence with Commissioner’s delegate – whether claimed invention is a patentable invention – whether claimed invention is a manner of manufacture within the meaning of the Statute of Monopolies – whether claimed invention is useful
Patents Act 1952 (Cth) s 100
Patents Act 1990 (Cth) ss 3, 7, 18, 138
Statute of Monopolies (21 Jac. 1, c. 3)Advanced Building Systems Pty Limited v Ramset Fasteners (Aust) Pty Limited (1998) 194 CLR 171 cited
Fawcett v Homan (1896) 13 RPC 398 cited
ICI Chemicals & Polymers Limited v The Lubrizol Corporation Inc (2000) 106 FCR 214 cited
IG Farbenindustrie AG’s Patents, Re (1930) 47 RPC 289 citedPfizer Overseas Pharmaceuticals v Ely Lilly & Co (2005) 225 ALR 416 cited
Prestige Group (Australia) Pty Limited v Dart Industries Inc (1990) 95 ALR 533 cited
Rehm Pty Limited v Webster’s Security Systems (International) Pty Limited (1981) 81 ALR 79 cited
Re IG Farbenindustrie AG’s Patents (1930) 47 RPC 289 at 322-3 cited
Synthetic Turf Development Pty Limited v Sports Technology International Pty Limited [2004] FCA 1179 cited
Welcome Real-Time SA v Catuity Inc (2001) 113 FCR 110 cited
WM Wrigley Jr Co v Cadbury Schweppes Pty Limited (2005) 66 IPR 298 citedRANBAXY AUSTRALIA PTY LTD (ACN 110 871 826) v WARNER-LAMBERT COMPANY LLC
VID90 OF 2007WARNER-LAMBERT COMPANY LLC v RANBAXY AUSTRALIA PTY LTD
(ACN 110 871 826)
VID93 OF 2007EMMETT, WEINBERG & BENNETT JJ
28 MAY 2008
MELBOURNE
IN THE FEDERAL COURT OF AUSTRALIA
VICTORIA DISTRICT REGISTRY
VID90 OF 2007
ON APPEAL FROM A SINGLE JUDGE OF THE FEDERAL COURT OF AUSTRALIA
BETWEEN:
RANBAXY AUSTRALIA PTY LTD (ACN 110 871 826)
Appellant
AND:
WARNER-LAMBERT COMPANY LLC
Respondent
JUDGES:
EMMETT, WEINBERG & BENNETT JJ
DATE OF ORDER:
28 MAY 2008
WHERE MADE:
MELBOURNE
THE COURT ORDERS THAT:
1.The appeal be dismissed.
Note: Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.
IN THE FEDERAL COURT OF AUSTRALIA
VICTORIA DISTRICT REGISTRY
VID93 OF 2007
ON APPEAL FROM A SINGLE JUDGE OF THE FEDERAL COURT OF AUSTRALIA
BETWEEN:
WARNER-LAMBERT COMPANY LLC
AppellantAND:
RANBAXY AUSTRALIA PTY LTD (ACN 110 871 826)
First RespondentCOMMISSIONER OF PATENTS
Second Respondent
JUDGES:
EMMETT, WEINBERG AND BENNETT JJ
DATE OF ORDER:
28 MAY 2008
WHERE MADE:
MELBOURNE
THE COURT ORDERS THAT:
1. The appeal be dismissed.
Note: Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.
TABLE OF CONTENTS
INTRODUCTION........ ........ ........ ........ ........ ........ ........ ........…
Keep reading for free
Create a free CaseChat account to read Ranbaxy Australia Pty Ltd v Warner-Lambert Co LLC and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2008] FCAFC 82
- Decision Date
CaseChat Overview and Summary
The court examined the claims of the patents and found that the broader patent issued to Warner-Lambert encompassed various forms of the compound, including specific enantiomers and mixtures. The court concluded that the claims in Warner-Lambert's enantiomer patent were not false suggestions and misrepresentations as Ranbaxy had argued, and therefore, there was no basis to invalidate the patent on those grounds. Consequently, the court did not need to address the issue of whether the enantiomer patent met the statutory requirement of being a 'manner of manufacture'. Based on these findings, the court dismissed both appeals, with no order as to costs due to the equitable distribution of outcomes between the parties.
The court's decision upheld the validity of Warner-Lambert's patent, ensuring that Ranbaxy could not challenge the exclusivity of Warner-Lambert's enantiomer-specific pharmaceutical compound. This ruling had implications for patent law in Australia, particularly in how specific enantiomers are treated in relation to broader chemical compositions and the criteria for patentability under the Statute of Monopolies.
Orders
Orders of the court
1. The appeal be dismissed.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.